[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis (author's transl)]
- PMID: 352084
[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis (author's transl)]
Abstract
The authors have studied the antispastic action of Dantrium in 50 patients with multiple sclerosis; in all cases, hypertonia, spasms or clonus constituted a severe obstacle to remedial therapy or nursing. After one year, the authors have found that Dantrium is effective in reducing hypertonia in 40% of the patients, in improving spasms in 65% and in reducing clonus in 50% of the cases. Secondary effects are fairly frequent (60%), characterized in most cases by diminished muscular strength and greater fatigability.